Ocean Biomedical, Inc. (OCEA) 10-Year Financial Performance & Capital Metrics

OCEA • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.Show more

Revenue $0
EBITDA $0 +100.0%
Net Income -$3M -683.8%
EPS (Diluted) -0.12 -153.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -98.81% -18408.4%
ROIC -
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Weak momentum: RS Rating 10 (bottom 10%)
✗Shares diluted 44.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM3.45%

ROCE

10Y Avg-1.68%

5Y Avg-1.68%

3Y Avg-1.68%

Latest-

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-
Gross Profit+	0	0	0	0	0
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-
Operating Expenses+	232K	1.65M	566.56K	2.48M	3.8M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	197K	1.6M	28.41M	2.48M	3.77M
SG&A % of Revenue	-	-	-	-	-
Research & Development	35K	49K	33.93M	0	26K
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	-61.78M	0	0
Operating Income+	-232K	-1.65M	-566.56K	-2.48M	0
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	-6.12%	0.66%	-3.38%	1%
EBITDA+	-60.14K	-1.45M	-330K	-957.74K	0
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	-23.04%	0.77%	-1.9%	1%
D&A (Non-Cash Add-back)	171.86K	206.3K	236.56K	0	0
EBIT	0	0	-564.11K	-957.74K	0
Net Interest Income+	0	0	2.45K	1.52M	0
Interest Income	0	0	2.45K	1.52M	0
Interest Expense	0	0	0	691	-2.05M
Other Income/Expense	0	-1K	2.45K	1.52M	0
Pretax Income+	-232K	-1.65M	-564.11K	-958.43K	-3.3M
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	0	0	0
Effective Tax Rate %	1%	1%	110.52%	-0.59%	1%
Net Income+	-232K	-1.65M	-62.34M	565.47K	-3.3M
Net Margin %	-	-	-	-	-
Net Income Growth %	-	-6.13%	-36.72%	1.01%	-6.84%
Net Income (Continuing)	-232K	-1.65M	-564.11K	-958.43K	-3.3M
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-0.01	-0.08	-0.04	-0.05	-0.12
EPS Growth %	-	-6.11%	0.48%	-0.11%	-1.53%
EPS (Basic)	-0.01	-0.08	-0.04	-0.05	-0.12
Diluted Shares Outstanding	20.2M	20.2M	13.22M	19.02M	27.5M
Basic Shares Outstanding	20.2M	20.2M	13.22M	19.02M	27.5M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Total Current Assets+	0	386K	1.55M	467.99K	812K
Cash & Short-Term Investments	0	0	1.08M	328.31K	0
Cash Only	0	0	1.08M	328.31K	0
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	50K	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	0	386K	0	0	224K
Total Non-Current Assets+	0	0	107.1M	110.44M	90K
Property, Plant & Equipment	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	0	0	0
Intangible Assets	0	0	0	0	0
Long-Term Investments	0	0	107.1M	110.44M	90K
Other Non-Current Assets	0	0	0	0	0
Total Assets+	0	386K	108.65M	110.91M	902K
Asset Turnover	-	-	-	-	-
Asset Growth %	-	-	280.48%	0.02%	-0.99%
Total Current Liabilities+	232K	2.27M	246.44K	3.46M	33.89M
Accounts Payable	0	53K	34.44K	0	799K
Days Payables Outstanding	-	-	-	-	-
Short-Term Debt	0	0	0	2.15M	16.3M
Deferred Revenue (Current)	0	0	0	0	0
Other Current Liabilities	-232K	0	0	0	1.09M
Current Ratio	-	0.17x	6.29x	0.14x	0.02x
Quick Ratio	-	0.17x	6.29x	0.14x	0.02x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	0	53K	3.15M	3.15M	64.63M
Long-Term Debt	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	64.63M
Total Liabilities	232K	2.27M	3.4M	6.61M	98.52M
Total Debt+	0	0	0	2.15M	16.3M
Net Debt	0	0	-60K	1.82M	16.3M
Debt / Equity	-	-	-	0.02x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-	-	-	-3591.37x	-
Total Equity+	-232K	-1.89M	105.26M	104.3M	-97.62M
Equity Growth %	-	-7.13%	56.84%	-0.01%	-1.94%
Book Value per Share	-0.01	-0.09	7.96	5.48	-3.55
Total Shareholders' Equity	-232K	-1.89M	105.26M	104.3M	-97.62M
Common Stock	0	0	107.1M	110.44M	0
Retained Earnings	-232K	-1.89M	-564.11K	-2.77M	-205.53M
Treasury Stock	0	0	0	0	0
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2024
Cash from Operations+	0	-64K	-1.05M	-747.3K	-4.18M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	-	-15.45%	0.29%	-4.59%
Net Income	-232K	-1.65M	-62.34M	-958.43K	-9.48M
Depreciation & Amortization	0	0	0	0	0
Stock-Based Compensation	0	0	56.55M	0	745K
Deferred Taxes	0	0	0	0	0
Other Non-Cash Items	0	0	0	-1.52M	3.51M
Working Capital Changes	232K	1.59M	4.74M	1.74M	1.04M
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	0	0	0	290.38K	869K
Cash from Investing+	0	0	-107.1M	-2.1M	0
Capital Expenditures	0	0	0	-3	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	3	0
Cash from Financing+	0	64K	1.11M	2.1M	3.4M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	0	64K	96K	0	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	0	-64K	-1.05M	-747.3K	-4.18M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	-	-15.45%	0.29%	-4.59%
FCF per Share	-	-0.00	-0.08	-0.04	-0.15
FCF Conversion (FCF/Net Income)	-	0.04x	0.02x	-1.32x	1.27x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2019	2020	2021	2022	2024
Return on Equity (ROE)	-	-	-120.62%	0.54%	-98.81%
Return on Invested Capital (ROIC)	-	-	-0.83%	-1.77%	-
Debt / Equity	-	-	-	0.02x	-
Interest Coverage	-	-	-	-3591.37x	-
FCF Conversion	-	0.04x	0.02x	-1.32x	1.27x

Frequently Asked Questions

Growth & Financials

Ocean Biomedical, Inc. (OCEA) grew revenue by 0.0% over the past year. Growth has been modest.

Ocean Biomedical, Inc. (OCEA) reported a net loss of $30.7M for fiscal year 2024.

Dividend & Returns

Ocean Biomedical, Inc. (OCEA) has a return on equity (ROE) of -98.8%. Negative ROE indicates the company is unprofitable.

Ocean Biomedical, Inc. (OCEA) had negative free cash flow of $4.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener